.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Merck
QuintilesIMS
McKesson
Dow
Teva
Novartis
Mallinckrodt
US Army
Cerilliant

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,310,094

« Back to Dashboard

Which drugs does patent 6,310,094 protect, and when does it expire?


Patent 6,310,094 protects ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, BREVIBLOC, BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, and BREVIBLOC IN PLASTIC CONTAINER, and is included in two NDAs. There has been one Paragraph IV challenge on Brevibloc.

Protection for BREVIBLOC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-three patent family members in twenty-four countries.

Summary for Patent: 6,310,094

Title: Ready-to-use esmolol solution
Abstract:A ready-to-use injectable, aqueous pharmaceutical composition for the treatment of cardiac conditions, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino) propoxy] phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture in a container, is disclosed.
Inventor(s): Liu; Jie (Scotch Plains, NJ), Pejaver; Satish K. (Bridgewater, NJ), Owoo; George (North Plainfield, NJ)
Assignee: Baxter International Inc. (Deerfield, IL)
Application Number:09/759,547
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Hq Spclt PharmaESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINEResmolol hydrochlorideSOLUTION;INTRAVENOUS205703-002Apr 7, 2016RXYesYes► Subscribe► Subscribe► SubscribeY
Hq Spclt PharmaESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINEResmolol hydrochlorideSOLUTION;INTRAVENOUS205703-001Apr 7, 2016RXYesYes► Subscribe► Subscribe► SubscribeY
Baxter HlthcareBREVIBLOCesmolol hydrochlorideINJECTABLE;INJECTION019386-006Feb 25, 2003APRXYesYes► Subscribe► Subscribe► SubscribeY
Baxter HlthcareBREVIBLOCesmolol hydrochlorideINJECTABLE;INJECTION019386-007May 28, 2003DISCNNoNo► Subscribe► Subscribe► SubscribeY
Baxter HlthcareBREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINEResmolol hydrochlorideINJECTABLE;INJECTION019386-005Jan 27, 2003RXYesYes► Subscribe► Subscribe► SubscribeY
Baxter HlthcareBREVIBLOC IN PLASTIC CONTAINEResmolol hydrochlorideINJECTABLE;INJECTION019386-004Feb 16, 2001RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,310,094

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,528,540 Esmolol formulation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,310,094

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia12782002► Subscribe
Slovenia1368019► Subscribe
Russian Federation2286774► Subscribe
Russian Federation2002132189► Subscribe
Portugal1368019► Subscribe
Poland216192► Subscribe
Poland357387► Subscribe
MexicoPA03006229► Subscribe
Japan2013151572► Subscribe
Japan2004519506► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Citi
Dow
Harvard Business School
Boehringer Ingelheim
Cerilliant
Healthtrust
Cantor Fitzgerald
US Army
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot